Boston Scientific Reports Strong Q4 Results but Issues Cautious 2026 Outlook

Boston Scientific Corporation released its financial results for the fourth quarter of 2025, posting net sales of $5.286 billion. This represents an increase of 15.9% compared to the same period last year.

The company's earnings were higher than what analysts had expected for the quarter. However, one of Boston Scientific's key divisions, electrophysiology, reported sales below forecasts.

Despite the strong performance in the fourth quarter, Boston Scientific shared a cautious revenue and profit forecast for 2026. This outlook was slightly below what Wall Street was predicting.

As a result of the conservative forecast and below-expectation sales in a major division, Boston Scientific's stock dropped more than 11% in premarket trading.

While the company's earnings beat expectations, their forecast for 2026 was lower than analysts had hoped, and one important division missed its sales targets. This made investors worried about future growth.

The electrophysiology division deals with devices and treatments for heart rhythm disorders. It's a significant area for Boston Scientific, so lower sales in this division impact the company's overall outlook.

Sales rose 15.9% compared to the same period last year, reaching $5.286 billion.

Benzinga

Boston Scientific Corporation (NYSE: BSX) will release earnings for its fourth quarter before the opening bell on Wednesday, Feb. 4.

PRNewsWire

MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to t...

Barrons

The medical-device maker beats quarterly earnings expectations but offers a disappointing outlook for the current quarter.

Reuters

Boston Scientific Corp forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, overshadowing a strong fourth-quarter performance and sending its shares down more than 11% in premarket trading.

Investors Business Daily

Boston Scientific stock tumbled early Wednesday after its fourth-quarter electrophysiology sales came in light.

WSJ

Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.

Zacks Investment Research

GSK's Q4 earnings and sales top estimates as strong specialty medicine demand fuels growth and drives shares higher on an upbeat 2026 outlook.

Zacks Investment Research

Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research

While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research

BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.

The Motley Fool

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market.

Zacks Investment Research

ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.

Seeking Alpha

Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript

The Motley Fool

Expand NYSE: BSX Boston Scientific Today's Change (-17.50%) $-16.03 Current Price $75.59 Key Data Points Market Cap $136B Day's Range $75.00 - $81.68 52wk Range $75.00 - $109.50 Volume 3.3M Avg Vol 10M Gross Margin 62.57% Boston Scientific (BSX 17.50%), a medical-device maker for interventional spec...

Benzinga

Boston Scientific Corporation (NYSE: BSX) reported upbeat earnings for the fourth quarter on Wednesday.

Zacks Investment Research

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.67 per share a year ago.

Show All Sources